{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":2,"youtube":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"LIBRETTO-121","nct_id":"NCT03899792","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=libretto-121-nct03899792. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"LIBRETTO-121","arms":[{"description":"Participants in this cohort had MTC and received 160 mg of selpercatinib BID orally on Days 1 through 28 of a 28-day cycle.\n\nThe treatment was continued until participants experienced a progressive disease, unacceptable toxicity, or other protocol-defined reason for discontinuation.","label":"Cohort 1: Medullary Thyroid Cancer (MTC) Group","type":"EXPERIMENTAL"},{"description":"Participants in this cohort had PTC and received 160 mg of selpercatinib BID orally on Days 1 through 28 of a 28-day cycle.\n\nThe treatment was continued until participants experienced a progressive disease, unacceptable toxicity, or other protocol-defined reason for discontinuation.","label":"Cohort 2: Papillary Thyroid Cancer (PTC) Group","type":"EXPERIMENTAL"},{"description":"Participants in this cohort had other (REarranged during Transfection (RET)-altered non-thyroid) cancer and received 160 mg of selpercatinib BID orally on Days 1 through 28 of a 28-day cycle.\n\nThe treatment was continued until participants experienced a progressive disease, unacceptable toxicity, or other protocol-defined reason for discontinuation.","label":"Cohort 3: Other Cancer Group","type":"EXPERIMENTAL"}],"collaborators":["Loxo Oncology, Inc."],"completion_date":{"date":"2029-05","type":"ESTIMATED"},"conditions":["Medullary Thyroid Cancer","Infantile Myofibromatosis","Infantile Fibrosarcoma","Papillary Thyroid Cancer","Soft Tissue Sarcoma"],"enrollment":{"count":36,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Selpercatinib","type":"DRUG"}],"last_update":"2026-01-06","lead_sponsor":"Eli Lilly and Company","official_title":"A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2024-11-08","type":"ACTUAL"},"primary_outcomes":[{"measure":"Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)","timeFrame":"Cycle 1 (28 Day Cycle)"},{"measure":"Phase 2: Percentage of Participants With Overall Response Rate (ORR) in Study","timeFrame":"Date of first dose to disease progression or death (Up to 62.4 Months)"}],"references":[],"start_date":{"date":"2019-06-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors","url":"https://clinicaltrials.gov/study/NCT03899792"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/libretto-121-nct03899792"}